Pharmaceuticals, Biotechnology and Life Sciences
Novartis’s Gilenya became the first and only oral disease-modifying treatment for young patients with relapsing-remitting forms of multiple sclerosis (RRMS),…
Tiziana Life Sciences has started the first-in-human Phase 1 clinical trial in healthy volunteers for Foralumab , which will be given to…
ObsEva SA has started testing in third phase its oral oxytocin receptor antagonist, nolasiban, for the improvement of rates of pregnancy and live birth in patients undergoing assisted reproduction technology (ART), or in-vitro fertilization (IVF).
Novartis’s eye care division Alcon, on Tuesday has its first Capital Markets Day for investors and analysts as a tax-neutral,…
ADC Therapeutics has dosed the first patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), in a Phase I/II…
German privately financed vascular integrity company Adrenomed has closed a €24 million series D financing round co-led by Wellington Partners…
ViiV Healthcare and Janssen Sciences Ireland UC’s Juluca Combination Tablets for treating HIV (type 1) was approved by the Ministry…
Novartis’ Sandoz, received on Tuesday from the European Commission (EC) the marketing authorization for biosimilar Ziextenzo (pegfilgrastim), which is indicated to reduce the…
Novartis’ Luxturna, a one-time gene therapy for the treatment of patients with vision loss due to a genetic mutation, developed…
The U.S. FDA confirmed that data required for the submission can largely be based on clinical samples previously collected during…